Cargando…
494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period
BACKGROUND: Pre-exposure prophylaxis (PrEP) with a combination of long-acting monoclonal antibodies with tixagevimab/cilgavimab (T/C) have provided viral neutralizing activity against SARS-CoV-2 and protected solid organ transplant recipients (SOTRs) that produced poor immunogenicity after COVID-19...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678462/ http://dx.doi.org/10.1093/ofid/ofad500.563 |
_version_ | 1785150367429820416 |
---|---|
author | Rojanakit, Gun Kiertiburanakul, Sasisopin Boongird, Sarinya Sutharattanapong, Napan Yingchoncharoen, Teerapat Sobhonslidsuk, Abhasnee Bruminhent, Jackrapong |
author_facet | Rojanakit, Gun Kiertiburanakul, Sasisopin Boongird, Sarinya Sutharattanapong, Napan Yingchoncharoen, Teerapat Sobhonslidsuk, Abhasnee Bruminhent, Jackrapong |
author_sort | Rojanakit, Gun |
collection | PubMed |
description | BACKGROUND: Pre-exposure prophylaxis (PrEP) with a combination of long-acting monoclonal antibodies with tixagevimab/cilgavimab (T/C) have provided viral neutralizing activity against SARS-CoV-2 and protected solid organ transplant recipients (SOTRs) that produced poor immunogenicity after COVID-19 immunization. However, real-world data on the effectiveness and safety of T/C in SOTRs during the Omicron wave is limited. METHODS: A prospective study at a single transplant center was conducted to evaluate the effectiveness and adverse events (AE) of T/C among SOTRs during the BA.2.75 Omicron lineages period (August 2022 to February 2023). T/C of 150/150 and 300/300 mg doses were provided from August 2022 to December 2022 and after, respectively. RESULTS: A total of 39 SOTRs comprising kidney (n= 29), liver (n=2), and heart (n=8) transplant recipients were included in the study. Thirty-three (85%) and 6 (15%) SOTRs received 150/150 and 300/300 mg of T/C, respectively. The median (IQR) age was 52 (35-62) years. Twenty-two (56%) had a prior history of COVID-19. The median (IQR) number of COVID-19 vaccine was 4 (3-4) doses. During the median follow-up of 6.35 (5-8.33) months, COVID-19 developed in 5 (12.8%) out of 39 SOTRs with a median (IQR) time of 73 (36-115) days from receiving T/C. None of those who received a 300/300 mg dose developed COVID-19. There was no severe COVID-19 or death observed. Five (12.8%) SOTRs reported mild and reversible AEs with pain at injection (n=2), fever (n=3), and muscle aches (n=1). There was no allograft rejection reported. CONCLUSION: Breakthrough SARS-CoV-2 infection remains among fully vaccinated SOTRs receiving T/C as PrEP and subjects to concurrent circulating strain in the community. However, the disease severity appears mild, and the short-term safety profile seems tolerable. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-10678462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106784622023-11-27 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period Rojanakit, Gun Kiertiburanakul, Sasisopin Boongird, Sarinya Sutharattanapong, Napan Yingchoncharoen, Teerapat Sobhonslidsuk, Abhasnee Bruminhent, Jackrapong Open Forum Infect Dis Abstract BACKGROUND: Pre-exposure prophylaxis (PrEP) with a combination of long-acting monoclonal antibodies with tixagevimab/cilgavimab (T/C) have provided viral neutralizing activity against SARS-CoV-2 and protected solid organ transplant recipients (SOTRs) that produced poor immunogenicity after COVID-19 immunization. However, real-world data on the effectiveness and safety of T/C in SOTRs during the Omicron wave is limited. METHODS: A prospective study at a single transplant center was conducted to evaluate the effectiveness and adverse events (AE) of T/C among SOTRs during the BA.2.75 Omicron lineages period (August 2022 to February 2023). T/C of 150/150 and 300/300 mg doses were provided from August 2022 to December 2022 and after, respectively. RESULTS: A total of 39 SOTRs comprising kidney (n= 29), liver (n=2), and heart (n=8) transplant recipients were included in the study. Thirty-three (85%) and 6 (15%) SOTRs received 150/150 and 300/300 mg of T/C, respectively. The median (IQR) age was 52 (35-62) years. Twenty-two (56%) had a prior history of COVID-19. The median (IQR) number of COVID-19 vaccine was 4 (3-4) doses. During the median follow-up of 6.35 (5-8.33) months, COVID-19 developed in 5 (12.8%) out of 39 SOTRs with a median (IQR) time of 73 (36-115) days from receiving T/C. None of those who received a 300/300 mg dose developed COVID-19. There was no severe COVID-19 or death observed. Five (12.8%) SOTRs reported mild and reversible AEs with pain at injection (n=2), fever (n=3), and muscle aches (n=1). There was no allograft rejection reported. CONCLUSION: Breakthrough SARS-CoV-2 infection remains among fully vaccinated SOTRs receiving T/C as PrEP and subjects to concurrent circulating strain in the community. However, the disease severity appears mild, and the short-term safety profile seems tolerable. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678462/ http://dx.doi.org/10.1093/ofid/ofad500.563 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Rojanakit, Gun Kiertiburanakul, Sasisopin Boongird, Sarinya Sutharattanapong, Napan Yingchoncharoen, Teerapat Sobhonslidsuk, Abhasnee Bruminhent, Jackrapong 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period |
title | 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period |
title_full | 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period |
title_fullStr | 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period |
title_full_unstemmed | 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period |
title_short | 494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period |
title_sort | 494. real-world effectiveness of tixagevimab/cilgavimab for covid-19 pre-exposure prophylaxis in solid organ transplant recipients during the omicron variant period |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678462/ http://dx.doi.org/10.1093/ofid/ofad500.563 |
work_keys_str_mv | AT rojanakitgun 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod AT kiertiburanakulsasisopin 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod AT boongirdsarinya 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod AT sutharattanapongnapan 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod AT yingchoncharoenteerapat 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod AT sobhonslidsukabhasnee 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod AT bruminhentjackrapong 494realworldeffectivenessoftixagevimabcilgavimabforcovid19preexposureprophylaxisinsolidorgantransplantrecipientsduringtheomicronvariantperiod |